Human iPS cell-derived dopaminergic neurons function in a primate Parkinson’s disease model
The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Induced pluripotent stem cells (iPS cells) are a promising source for a cell-based therapy to treat Parkinson's disease (PD), in which midbrain dopaminergic neurons progressively degenerate. However, long-term analysis of human iPS cell-derived dopaminergic neurons in primate PD models has never been performed to our knowledge. Here we show that human iPS cell-derived dopaminergic progenitor cells survived and functioned as midbrain dopaminergic neurons in a primate model of PD (Macaca fascicularis) treated with the neurotoxin MPTP. Score-based and video-recording analyses revealed an increase in spontaneous movement of the monkeys after transplantation. Histological studies showed that the mature dopaminergic neurons extended dense neurites into the host striatum; this effect was consistent regardless of whether the cells were derived from patients with PD or from healthy individuals. Cells sorted by the floor plate marker CORIN did not form any tumours in the brains for at least two years. Finally, magnetic resonance imaging and positron emission tomography were used to monitor the survival, expansion and function of the grafted cells as well as the immune response in the host brain. Thus, this preclinical study using a primate model indicates that human iPS cell-derived dopaminergic progenitors are clinically applicable for the treatment of patients with PD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Morizane et al. and Kikuchi et al. both showed that an improvement of engraftment and reduced immune reaction were observed using MHC matching of iPSC-derived dopaminergic neurons in unlesioned non-human primates [98,99].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [99]
In the citing paper
“A comprehensive study of human iPSC-derived dopamine neuron progenitor cells expressing specific markers of the neural floor plate (CORIN+; FOXA2+; TUJ1+; PAX6−) and transplanted into a monkey model of Parkinson’s disease showed stronger evidence of behavioural benefits, of cellular integration of mature dopamine neurons within the putamen, and of extension of their dense neurites into the host st”
From How to design preclinical studies in nanomedicine and cell therapy to maximize the prospects of clinical translation (2018) · cites this paper as [82]
In the citing paper
“Most of the transplanted cells expressed FOXA2 and a third expressed tyrosine hydroxylase consistent with mature functional dopamine neurons.”
From How to design preclinical studies in nanomedicine and cell therapy to maximize the prospects of clinical translation (2018) · cites this paper as [82]
Citations
Cites
Advances in functional and structural MR image analysis and implementation as FSL
Smith, S. M., Jenkinson, M., Woolrich, M. W., Beckmann, C. F., Behrens, T. E. J., Johansen-Berg, H., Bannister, P. R., De Luca, M., Drobnjak, I., Flitney, D. E., et al. (2004) · NeuroImage · doi:10.1016/j.neuroimage.2004.07.051 · Cited by 13,630
Jenkinson, M., Bannister, P., Brady, M., & Smith, S. (2002) · NeuroImage · doi:10.1006/nimg.2002.1132 · Cited by 11,888
Fast robust automated brain extraction
Smith, S. M. (2002) · Human Brain Mapping · doi:10.1002/hbm.10062 · Cited by 10,496
Zhang, Y., Brady, M., & Smith, S. (2001) · IEEE Transactions on Medical Imaging · doi:10.1109/42.906424 · Cited by 6,982
A global optimisation method for robust affine registration of brain images
Jenkinson, M., & Smith, S. (2001) · Medical Image Analysis · doi:10.1016/s1361-8415(01)00036-6 · Cited by 6,872
Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling
Chambers, S. M., Fasano, C. A., Papapetrou, E. P., Tomishima, M., Sadelain, M., & Studer, L. (2009) · Nature Biotechnology · doi:10.1038/nbt.1529 · Cited by 3,620
Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data
Patlak, C. S., Blasberg, R. G., & Fenstermacher, J. D. (1983) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1983.1 · Cited by 3,567
Transplantation of Embryonic Dopamine Neurons for Severe Parkinson's Disease
Freed, C. R., Greene, P. E., Breeze, R. E., Tsai, W.-Y., DuMouchel, W., Kao, R., Dillon, S., Winfield, H., Culver, S., Trojanowski, J. Q., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103083441002 · Cited by 2,366
Kriks, S., Shim, J.-W., Piao, J., Ganat, Y. M., Wakeman, D. R., Xie, Z., Carrillo-Reid, L., Auyeung, G., Antonacci, C., Buch, A., et al. (2011) · Nature · doi:10.1038/nature10648 · Cited by 1,907
Patlak, C. S., & Blasberg, R. G. (1985) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1985.87 · Cited by 1,673
Cited by
Items 301–400 of 705
Chen, Y., Kuang, J., Niu, Y., Zhu, H., Chen, X., So, K., Xu, A., & Shi, L. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.378203 · Cited by 14
“In recent years, tremendous progress has been made in generating mDA neurons by mimicking embryonic developmental signaling in stem cells, with some researchers having successfully conducted preclinical studies (Kikuchi et al., 2017; Doi et al., 2020; Xiong et al., 2021).”
BackgroundLü, Z., Zhao, R., Li, Y., Wang, J., Guo, J., Bai, C., Chen, J., Yang, J., Geng, Y., Zhang, T., et al. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2023.09.004 · Cited by 16
Wu, S., Lin, T., & Xu, Y. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-05006-0 · Cited by 14
“Induced pluripotent stem cells (iPSC) derived from PD patients offer a unique opportunity to study the pathogenesis of PD [2].”
BackgroundGordián‐Vélez, W. J., Browne, K. D., Galarraga, J. H., Chouhan, D., Duda, J. E., España, R. A., Chen, H.-C. I., Burdick, J. A., & Cullen, D. K. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202402997 · Cited by 19
Takahashi, R., Nakanishi, E., Yamakado, H., Sawamoto, N., & TAKAHASHI, J. C. (2025) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2025.107833 · Cited by 16
Self-citationPrimate stem cells: bridge the translation from basic research to clinic application
Li, T., Ai, Z., & Ji, W. (2018) · Science China Life Sciences · doi:10.1007/s11427-018-9334-2 · Cited by 14
Menon, V., Thomas, R., Elgueta, C., Horl, M., Osborn, T. M., Hallett, P. J., Bartos, M., Isacson, O., & Pruszak, J. (2019) · Stem Cells · doi:10.1002/stem.3057 · Cited by 17
Jhao, Y.-T., Chiu, C.-H., Chen, C. F., Chou, T.-K., Lin, Y., Ju, Y., Wu, S., Yan, R.-F., Shiue, C., Chueh, S., et al. (2019) · Cells · doi:10.3390/cells8111420 · Cited by 16
Wuli, W., Tsai, S., Chiou, T., & Harn, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041327 · Cited by 16
Adachi, H., Morizane, A., Torikoshi, S., Raudzus, F., Taniguchi, Y., Miyamoto, S., Sekiguchi, K., & Takahashi, J. A. (2022) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szac033 · Cited by 15
Self-citationLessons learnt, and still to learn, in first in human stem cell trials
Barker, R. A., Carpenter, M., Jamieson, C. H. M., Murry, C. E., Pellegrini, G., Rao, R. C., & Song, J. (2022) · Stem Cell Reports · doi:10.1016/j.stemcr.2022.11.019 · Cited by 16
Nakashima, Y., Miyagi‐Shiohira, C., Noguchi, H., & Ōmasa, T. (2018) · Brain Sciences · doi:10.3390/brainsci8090167 · Cited by 14
Chen, S.-D., Li, H., Cui, M., Dong, Q., & Yu, J. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1767579 · Cited by 15
Induced Pluripotent Stem Cells: Hope in the Treatment of Diseases, including Muscular Dystrophies
Beghini, D. G., Horita, S. I. M., Cascabulho, C. M., Alves, L. A., & Henriques‐Pons, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155467 · Cited by 24
Targeting cell plasticity for regeneration: From in vitro to in vivo reprogramming
Romanazzo, S., Lin, K., Srivastava, P., & Kilian, K. A. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.08.007 · Cited by 17
“Based on the safety and efficacy studies in rodent [6] and promising preclinical trial results in primates [226,227], millions of dopaminergic precursor cells that were derived from HLA homozygous allogeneic iPSC have been implanted in the patient’s brain in Kyoto University [228,229].”
BackgroundShrigley, S., Nilsson, F., Mattsson, B., Fiorenzano, A., Mudannayake, J. M., Bruzelius, A., Ottosson, D. R., Björklund, A., Hoban, D. B., & Parmar, M. (2020) · Journal of Parkinson s Disease · doi:10.3233/jpd-202366 · Cited by 16
“These studies demonstrate that DA progenitors derived from sporadic PD patients are capable of producing DA-rich grafts that mediate functional recovery both in rodent [27–29] and primate models of PD [11].”
BackgroundResultSelf-citationNishimura, K., & Takata, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22169047 · Cited by 15
Two decades of induced pluripotent stem cell research: From discovery to diverse applications
Yamanaka, S. (2026) · Cell stem cell · doi:10.1016/j.stem.2026.02.003 · Cited by 21
Parkinson's disease: pathogenesis and therapeutic strategies
Zhang, S., Wang, T., Peng, Y., Wang, Q., Zhang, Z., Shifeng, C. H. U., Huang, H., & Chen, N. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00445-0 · Cited by 22
“Stem cell therapy, as a highly promising disease-modifying strategy, has achieved key clinical progress in recent years [211].”
Stem Cell Transplantation for Parkinson’s Disease: Current Challenges and Perspectives
Zeng, X., & Qin, H. (2022) · Aging and Disease · doi:10.14336/ad.2022.0312 · Cited by 16
“That study demonstrated the key role of the epigenetic changes that occur in stem cell transplantation in the upregulation of genes related to dopaminergic neuron differentiation [52].”
BackgroundMidbrain organoids—development and applications in Parkinson’s disease
Toh, H. S. Y., Choo, X. Y., & Sun, A. X. (2023) · Oxford Open Neuroscience · doi:10.1093/oons/kvad009 · Cited by 15
“Since then, there have been numerous attempts at transplanting hPSC-derived dopaminergic grafts[167–169],includingsomethattransplantedgraftsintonon-human primates [170–172].”
BackgroundDopaminergic Cell Replacement for Parkinson’s Disease: Addressing the Intracranial Delivery Hurdle
Maheshwari, S., Akram, H., Bulstrode, H. J. C. J., Kalia, S. K., Morizane, A., Takahashi, J. B., & Natalwala, A. (2024) · Journal of Parkinson s Disease · doi:10.3233/jpd-230328 · Cited by 20
Self-citationSingh, C. S. B., Johns, K. M., Kari, S., Munro, L., Mathews, A., Fenninger, F., Pfeifer, C. G., & Jefferies, W. A. (2024) · Stem Cell Reports · doi:10.1016/j.stemcr.2024.02.012 · Cited by 13
Neural Stem Cell Therapy for Alzheimer’s Disease: A-State-of-the-Art Review
Shah, A. J., Dar, M. Y., Jan, B., Qadir, I., Mir, R. H., Uppal, J., Ahmad, N. Z., & Masoodi, M. H. (2024) · Journal of dementia and Alzheimer's disease · doi:10.3390/jdad1020008 · Cited by 14
“Limited availability of reliable animal models for AD mouse models hinders the establishment of disease-modifying treatment approaches, while primitive non-human Parkinson disease (PD) models offer intriguing possibilities for neuronal replacement treatment strategies [80,81].”
Li, S., Zhang, H., Wang, A., Liu, Y., Liu, H., Yue, F., Abulaiti, X., Zhang, C., & Li, L. (2019) · Molecular Medicine · doi:10.1186/s10020-019-0076-3 · Cited by 13
Yang, C., Wang, X., Tang, X., Wang, R., & Bao, X. (2019) · World Neurosurgery · doi:10.1016/j.wneu.2019.10.087 · Cited by 13
A technique for removing tumourigenic pluripotent stem cells using rBC2LCN lectin
Haramoto, Y., Onuma, Y., Mawaribuchi, S., Nakajima, Y., Aiki, Y., Higuchi, K., Shimizu, M., Tateno, H., Hirabayashi, J., & Ito, Y. (2020) · Regenerative Therapy · doi:10.1016/j.reth.2020.03.017 · Cited by 16
“Another has been initiated for banked allogeneic hiPSCs to treat Parkinson's disease [6].”
BackgroundYamagishi, H., & Shigematsu, K. (2021) · JMA Journal · doi:10.31662/jmaj.2021-0080 · Cited by 20
“They are moving forward with a clinical study in which allogeneic iPS cells generated from human cells with a type of HLA that is less prone to immune rejection are transformed into RPE cells, and a suspension containing the cells is transplanted into the patient’s eye (13), ((18)).”
BackgroundStem cell-derived exosomal MicroRNAs: Potential therapies in diabetic kidney disease
Wang, H., Wang, J., Liu, T., Leng, Y., & Yang, W. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114961 · Cited by 14
Harberts, J. I., Kusch, M., O’Sullivan, J., Zierold, R., & Blick, R. H. (2020) · Bioengineering · doi:10.3390/bioengineering7020046 · Cited by 13
Transplantation of Stem Cells as a Potential Therapeutic Strategy in Neurodegenerative Disorders
Ebrahimi, T., Abasi, M., Seifar, F., Eyvazi, S., Hejazi, M. S., Tarhriz, V., & Montazersaheb, S. (2020) · Current Stem Cell Research & Therapy · doi:10.2174/1574888x15666200628141314 · Cited by 18
Visualizing advances in the future of primate neuroscience research
Janssen, P., Isa, T., Lanciego, J. L., Leech, K., Logothetis, N. K., Poo, M., & Mitchell, A. S. (2022) · Current Research in Neurobiology · doi:10.1016/j.crneur.2022.100064 · Cited by 13
Sarmah, H., Sawada, A., Hwang, Y., Miura, A., Shimamura, Y., Tanaka, J., Yamada, K., & Mori, M. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1070560 · Cited by 13
“In another pre-clinical study, human iPS cellderived dopaminergic neurons showed functional engraftment in a neurotoxin-induced model of Parkinson’s disease (Kikuchi et al., 2017).”
BackgroundChallenges involved in cell therapy for Parkinson’s disease using human pluripotent stem cells
Moon, H., Kim, B., Kwon, I., & Oh, Y. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1288168 · Cited by 18
Columnar Injection for Intracerebral Cell Therapy
Schweitzer, J. S., Song, B., Leblanc, P. R., Feitosa, M., Carter, B. S., & Kim, K. (2019) · Operative Neurosurgery · doi:10.1093/ons/opz143 · Cited by 13
Neurons derived from human-induced pluripotent stem cells express mu and kappa opioid receptors
Cui, X., Ju, Z., Liang, X., Ren, Y., Luo-wa, S., & Yan, Y. (2020) · Neural Regeneration Research · doi:10.4103/1673-5374.295341 · Cited by 12
“The emergence of induced pluripotent stem (iPS) cells has injected vitality into the study of regenerative medicine, disease model establishment, and drug and toxicity screening (Lancaster et al., 2013; Kikuchi et al., 2017).”
BackgroundLiang, L., Tian, Y., Feng, L., Wang, C., Feng, G., Stacey, G. N., Shyh‐Chang, N., Wu, J., Hu, B., Li, W., et al. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-03104-7 · Cited by 14
Deficiency of miR-29a/b1 leads to premature aging and dopaminergic neuroprotection in mice
Bai, X., Wang, J., Zhang, X., Tang, Y., He, Y., Zhao, J., Han, L., Fang, R., Liu, Z., Dong, H., et al. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.978191 · Cited by 11
A cell fitness selection model for neuronal survival during development
Wang, Y., Wu, H., Fontanet, P., Codeluppi, S., Akkuratova, N., Petitpré, C., Xue‐Franzén, Y., Niederreither, K., Sharma, A., Silva, F. D., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12119-3 · Cited by 12
Preclinical evaluation of patient-derived cells shows promise for Parkinson’s disease
Takahashi, J. B. (2020) · Journal of Clinical Investigation · doi:10.1172/jci134031 · Cited by 13
Self-citationToward Generating Subtype-Specific Mesencephalic Dopaminergic Neurons in vitro
Cardoso, T., & Lévesque, M. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00443 · Cited by 14
Brain Repair by Cell Replacement via In Situ Neuronal Reprogramming
Qian, H., & Fu, X. (2021) · Annual Review of Genetics · doi:10.1146/annurev-genet-071719-023616 · Cited by 14
Transcriptome Dynamics of Human Neuronal Differentiation From iPSC
Kuruş, M., Akbari, S., Eskier, D., Bursalı, A., Ergin, K., Erdal, E., & Karakülah, G. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.727747 · Cited by 13
“Moreover, increase in our knowledge about the coordination of brain development has permitted to develop specific regions of the brain in vitro (Muratore et al., 2014; Tao and Zhang, 2016; Kikuchi et al., 2017).”
BackgroundHurtado, J. C., Berrío, J. P., Rodrigues, C., Zancan, M., Wink, M. R., & de Oliveira, A. A. (2019) · Journal of Neuroscience Research · doi:10.1002/jnr.24442 · Cited by 14
“…in rodent and primate models of neu‐ rodegenerative syndromes such as Alzheimer's and Parkinson's disease (Berrío Sánchez, Cucarián Hurtado, & de Oliveira, 2017; Fu et al., 2015; Kikuchi et al., 2017; McGinley et al., 2018; Moon et al., 2013; Yang, Zhang, Oldenburg, Ayala, & Zhang, 2008).”
BackgroundWang, X., Han, D., Zheng, T., Ma, J., & Chen, Z. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03921-y · Cited by 11
Emborg, M. E., Metzger, J. M., D’Amour, K. A., Colwell, J. C., Neumann, L., Zhang, A., & Federoff, H. J. (2025) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2025.111297 · Cited by 11
“Daily doses of tacrolimus to parkinsonian cynomolgus macaques allowed survival of human iPSC-derived dopaminergic neurons up to 2 years, yet the long-term efficacy of the grafts was unclear as the reported behavioral data was limited to the 1st year after transplantation (Kikuchi et al., 2017).”
InfluentialMorizane, A., Yamasaki, E., Shindo, T., Anazawa, T., Sawamoto, N., Shima, A., Yamakado, H., Nakanishi, E., Sawamura, M., Taruno, Y., et al. (2025) · Cell stem cell · doi:10.1016/j.stem.2025.07.012 · Cited by 16
Self-citationAbe, H., Iwama, T., Yabu, H., Ino, K., Inoue, K. Y., Suda, A., Kunikata, R., Matsudaira, M., & Matsue, T. (2018) · Electroanalysis · doi:10.1002/elan.201800386 · Cited by 11
Transplantable human motor networks as a neuron-directed strategy for spinal cord injury
Olmsted, Z. T., Stigliano, C., Scimemi, A., Wolfe, T., Cibelli, J. B., Horner, P. J., & Paluh, J. L. (2021) · iScience · doi:10.1016/j.isci.2021.102827 · Cited by 12
Parkinson's disease: Present and future of cell therapy
Sancho-Bielsa, F. J. (2022) · Neurology Perspectives · doi:10.1016/j.neurop.2021.07.006 · Cited by 12
100 plus years of stem cell research—20 years of ISSCR
Lendahl, U. (2022) · Stem Cell Reports · doi:10.1016/j.stemcr.2022.04.004 · Cited by 18
“The first PD patients have recently been grafted with iPS-derived neurons (Schweitzer et al., 2020; Takahashi, 2020; see also Kim et al., 2020; Parmar and Björklund, 2020 for review).”
BackgroundReal, C. C., Binda, K. H., Thomsen, M. B., Lillethorup, T. P., Brooks, D. J., & Landau, A. M. (2023) · Current Neuropharmacology · doi:10.2174/1570159x21666230216101659 · Cited by 11
Nikitina, A. A., Grouw, A. V., Roysam, T., Huang, D., Fernández, F. M., & Kemp, M. L. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.2c04416 · Cited by 11
Daadi, E. W., Daadi, E. S., Oh, T. T., Li, M., Kim, J., & Daadi, M. M. (2024) · Experimental Neurology · doi:10.1016/j.expneurol.2024.114694 · Cited by 15
Yang, X., Wang, R., Wang, X., Cai, G., Qian, Y., Feng, S., Tan, F., Chen, K., Tang, K., Huang, X., et al. (2018) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjy013 · Cited by 11
Okumura, H., Nakanishi, A., Toyama, S., Yamanoue, M., Yamada, K., Ukai, A., Hashita, T., Iwao, T., Miyamoto, T., Tagawa, Y., et al. (2018) · Xenotransplantation · doi:10.1111/xen.12468 · Cited by 10
Mishima, T., Fujioka, S., Fukae, J., Yuasa‐Kawada, J., & Tsuboi, Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123870 · Cited by 13
Chohan, M. O. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00116 · Cited by 11
A nonhuman primate model of liver fibrosis towards cell therapy for liver cirrhosis
Yasuda, K., Kotaka, M., Toyohara, T., Sueta, S., Katakai, Y., Ageyama, N., Üemoto, S., & Osafune, K. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.03.148 · Cited by 11
Possible Roles of Epigenetics in Stem Cell Therapy for Parkinson’s Disease
Thompson, C., Otero, P., Srinageshwar, B., Petersen, R. B., Dunbar, G. L., & Rossignol, J. (2020) · Epigenomics · doi:10.2217/epi-2019-0347 · Cited by 14
Morita, Y., Kishino, Y., Fukuda, K., & Tohyama, S. (2022) · Cell Proliferation · doi:10.1111/cpr.13248 · Cited by 14
“As a simulation of a clinical trial, approximately 5 10(6) cells were transplanted into the bilateral putamen of the Parkinson's disease model monkeys, and the monkeys were followed up for 2 years.(112) Historical analysis showed that more than 1 10(5) dopaminergic neurons survived per monkey, and there was no tumor f…”
MethodApplication of induced pluripotent stem cells to primary immunodeficiency diseases
Karagiannis, P., Yamanaka, S., & Saito, M. K. (2019) · Experimental Hematology · doi:10.1016/j.exphem.2019.01.005 · Cited by 14
The occurrence and development of induced pluripotent stem cells
Chen, Y., Li, M., & Wu, Y. (2024) · Frontiers in Genetics · doi:10.3389/fgene.2024.1389558 · Cited by 18
“Kikuchi et al. showed that the transplantation of midbrain dopamine neurons derived from human iPSCs into primate PD models achieved good function within 2 years, achieved the expected results, and did not cause severe immune responses (Kikuchi et al., 2017).”
BackgroundRegenerative rehabilitation: a novel multidisciplinary field to maximize patient outcomes
Deng, C., Aldali, F., Luo, H., & Chen, H. (2024) · Medical Review · doi:10.1515/mr-2023-0060 · Cited by 13
“Application of induced pluripotent stem cells (iPSCs) has sound e ff ects on AMD [22 – 24], Parkinson ’ s syndrome [25, 26], and other diseases [27 – 29].”
BackgroundLuo, F., Luo, S., Qian, W., Zhang, L., Chen, C., Xu, M., Wang, G., Wang, Z., Wang, J., & Wang, W. (2020) · Stem Cell Research · doi:10.1016/j.scr.2020.102027 · Cited by 10
Liu, J., Geng, R., Zhong, Z., Zhang, Y., Ni, S., Liu, W., Du, M., & Bai, J. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/2754836 · Cited by 13
“Induced pluripotent stem cells (IPS), ranging from 0 to 10, were evaluated in the light of the gene expression Z score, with higher IPS representing higher immunogenicity [30].”
Lee, S., Shim, H. S., Park, H. J., Chang, Y., Han, Y.-E., Oh, S., Lee, W., Im, H., Seol, Y., Ryu, H., et al. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.07.058 · Cited by 10
Sequestration of Inflammation in Parkinson’s Disease via Stem Cell Therapy
Gordon, J., Lockard, G., Monsour, M., Alayli, A., Choudhary, H., & Borlongan, C. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231710138 · Cited by 11
“Whether grafted from PD or control donors, iPSCs survive, make connections, and lead to functional recovery in monkeys [90].”
BackgroundWenker, S. D., Farías, M. I., Gradaschi, V., Garcia, C. I., Beauquis, J., Leal, M. C., Ferrari, C. C., Zeng, X., & Pitossi, F. J. (2023) · PLoS ONE · doi:10.1371/journal.pone.0263021 · Cited by 12
Miyawaki, Y., Samata, B., Kikuchi, T., Nishimura, K., & Takahashi, J. B. (2020) · Journal of Neuroscience Research · doi:10.1002/jnr.24668 · Cited by 12
“Another concern is that only a small fraction of grafted cells survive after transplantation, and the final yield of DA neuron is only about 0.3%– 2% the number of the transplanted cells (Doi et al., 2014; Kikuchi et al., 2017).”
BackgroundInfluentialSelf-citationInduced Pluripotent Stem Cells from Cancer-Resistant Naked Mole-Rats
Miura, K., Oiwa, Y., & Kawamura, Y. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-65943-1_13 · Cited by 13
Olmsted, Z. T., Stigliano, C., Marzullo, B. J., Cibelli, J. B., Horner, P. J., & Paluh, J. L. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.725195 · Cited by 12
“Parkinson’s disease has seen great advancements by applying new stem cell neural differentiation technologies that provide anatomic regional matching and cell-type specific replacement (A9 dopaminergic neurons and their precursors; Kikuchi et al., 2017; Xiong et al., 2021).”
BackgroundLi, M., Wang, Z., Zheng, T., Huang, T., Liu, B., Han, D., Liu, S., Liu, B., Li, M., Si, W., et al. (2022) · Stem Cells International · doi:10.1155/2022/1396735 · Cited by 10
Recent Advances in Extracellular Matrix for Engineering Stem Cell Responses
Guan, S., Zhang, K., & Li, J. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190704121309 · Cited by 10
Neuronal Vulnerability to Degeneration in Parkinson’s Disease and Therapeutic Approaches
Sharma, T., Kumar, R., & Mukherjee, S. (2023) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527322666230426155432 · Cited by 9
Gima, S., Oe, K., Nishimura, K., Ohgita, T., Ito, H., Kimura, H., Saito, H., & Takata, K. (2024) · Regenerative Therapy · doi:10.1016/j.reth.2023.12.019 · Cited by 10
“Preclinical studies using positron emission tomography (PET) provided noninvasive imaging of dopamine reuptake in grafted hiPSC-derived DA neurons, dividing cell proliferation, and immune cell in fl ammation response to monitor the cellular aspects in long-term follow-up [5,8,39].”
BackgroundChang, M., & Lee, S. (2025) · Yonsei Medical Journal · doi:10.3349/ymj.2024.0447 · Cited by 11
Qarin, S., Howlett, S., Jones, J., & Barker, R. A. (2021) · Neuronal Signaling · doi:10.1042/ns20200083 · Cited by 9
Comparative efficacy of surgical approaches to disease modification in Parkinson disease
Rahimpour, S., Zhang, S., Vitek, J. L., Mitchell, K. T., & Turner, D. A. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-022-00296-w · Cited by 11
Du, W., Cui, L., Zhang, J., Zhang, H., Liu, R., Yang, W., & Zhang, Y. (2022) · FEBS Open Bio · doi:10.1002/2211-5463.13460 · Cited by 9
Ahrabi, B., Mirakabad, F. S. T., Niknazar, S., Payvandi, A. A., Roozbahany, N. A., Ahrabi, M., Torkamani, S. D., & Abbaszadeh, H. (2022) · Journal of lasers in medical sciences · doi:10.34172/jlms.2022.28 · Cited by 10
Treatment of Parkinson's Disease: Current Treatments and Recent Therapeutic Developments
Wal, A., Wal, P., Vig, H., Jain, N. K., Rathore, S., Krishnan, K., & Srivastava, A. (2023) · Current Drug Discovery Technologies · doi:10.2174/1570163820666230512100340 · Cited by 10
López-Ornelas, A., Escobedo-Ávila, I., Ramirez‐Garcia, G., Lara-Rodarte, R., Meléndez-Ramírez, C., Urrieta-Chávez, B., Barrios‐García, T., Cáceres-Chávez, V. A., Flores-Ponce, X., Carmona, F., et al. (2023) · Cells · doi:10.3390/cells12232738 · Cited by 10
“Previous reports of grafting DANs differentiated from human stem cells showed that cell therapy induces improvements in parkinsonian NHPs regarding motor behavior and DA uptake sites assessed by PET [16,17,35].”
BackgroundMethodResultInfluentialCan pluripotent/multipotent stem cells reverse Parkinson’s disease progression?
Wu, Y., Meng, X., Cheng, W., Yan, Z., Li, K., Wang, J., Jiang, T., Zhou, F., Wong, K., Zhong, C., et al. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1210447 · Cited by 9
Zhao, Y., Liu, P., Wang, Y., Ma, Y., Guo, W., & Shi, C. (2024) · Experimental Neurology · doi:10.1016/j.expneurol.2024.114848 · Cited by 11
Shimizu, Y., Nakamura, Y., Horibata, Y., Fujimaki, M., Hayashi, K., Uchida, N., Morita, H., Arai, R., Chibana, K., Takemasa, A., et al. (2020) · Regenerative Therapy · doi:10.1016/j.reth.2020.03.007 · Cited by 10
Parmar, M., Björklund, A., & Björklund, T. (2021) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2021.06.002 · Cited by 10
Self-citationGuo, Y., Guan, Y., Zhu, H., Sun, T., Wang, Y., Huang, Y., Ma, C., Emery, R., Guan, W., Wang, C., et al. (2022) · Neurochemistry International · doi:10.1016/j.neuint.2022.105324 · Cited by 9
Mine, Y., Momiyama, T., Hayashi, T., & Kawase, T. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.06.007 · Cited by 10
Self-citationTang, Y., Han, Y., Yu, H., Zhang, B., & Li, G. (2020) · Neuroscience Letters · doi:10.1016/j.neulet.2020.135208 · Cited by 11
Current state of stem cell research in non-human primates: an overview
Wu, J., Shi, Y., Yang, S., Tang, Z., Li, Z., Li, Z., Zuo, J., Ji, W., & Niu, Y. (2023) · Medical Review · doi:10.1515/mr-2023-0035 · Cited by 11
“Induced DA neurons from iPSCs derived from sporadic PD patients can improve the behavior of NHPs with PD [54].”
BackgroundYang, Y., Li, X., Lu, J., Ge, J., Chen, M., Yao, R., Tian, M., Wang, J., Liu, F., & Zuo, C. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.391180 · Cited by 9
“However, an apparent increase in the binding potential of 11 C-PE2I PET was detected only in some monkeys with DAT + cells (Kikuchi et al., 2017).”
BackgroundCircuit integration by transplanted human neurons
Yuan, Q., & Zhang, S. (2024) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2024.102225 · Cited by 8
Yi, L., Woon, H. R., Saw, G., Zeng, L., Tan, E., & Zhou, Z. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-00771 · Cited by 8
“…models have been widely used in research on neurological disorders, including AD (Essayan-Perez et al., 2019), PD (Cooper et al., 2010; Kriks et al., 2011; Kikuchi et al., 2017), Huntington’s disease (Mattis and Svendsen, 2017), and amyotrophic lateral sclerosis (Lee and Huang, 2017).”
Shao, X., Li, M., Shi, S., Wu, T., Zhang, Y., Guo, S., Lin, H., & Qi, X. (2025) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x25500314 · Cited by 11
Physical and mechanical properties of metallic biomaterials
Nakano, T. (2019) · Elsevier eBooks · doi:10.1016/b978-0-08-102666-3.00003-1 · Cited by 8
Liang, K. X., Chen, A., Kristiansen, C. K., & Bindoff, L. A. (2021) · Journal of Visualized Experiments · doi:10.3791/63116 · Cited by 8
Sheref, A. A. M., Naguib, Y. M., Abouelnour, E., Salem, H. R., Hassan, M. Y., & ABDEL-RAZEK, H. (2022) · Bulletin of Egyptian Society for Physiological Sciences · doi:10.21608/besps.2021.71203.1099 · Cited by 7
Immortal orexin cell transplants restore motor-arousal synchrony during cataplexy
Pintwala, S. K., Fraigne, J. J., Belsham, D. D., & Peever, J. H. (2023) · Current Biology · doi:10.1016/j.cub.2023.03.077 · Cited by 10
Urasawa, T., Koizumi, T., Kimura, K., Ohta, Y., & Kawasaki, N. (2023) · Journal of Proteome Research · doi:10.1021/acs.jproteome.2c00841 · Cited by 8
Metadata
- Authors
- Kikuchi, T., Morizane, A., Doi, D., Magotani, H., Onoe, H., Hayashi, T., Mizuma, H., Takara, S., Takahashi, R., Inoue, H., Morita, S., Yamamoto, M., Okita, K., Nakagawa, M., Parmar, M., & Takahashi, J.
- Affiliations
- Kyoto University (JP)
- RIKEN (JP)
- Lund University (SE)
- Corresponding author
- Takahashi, Jun
- ORCID
- Venue
- Nature
- Published
- 2017-08
- Volume
- 548
- Issue
- 7669
- Pages
- 592-596
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2751466955
- Cited by
- 702
- References
- 48
- Citations by year
- 2026: 33 · 2025: 53 · 2024: 74 · 2023: 69 · 2022: 91 · 2021: 89 · 2020: 123 · 2019: 88 · 2018: 75 · 2017: 6
- FWCI
- 32.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- Japan Society for the Promotion of Science (15H02502, 15H02540, 16H03306, 15K12779, 16H03300)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- Parkinson's disease, dopaminergic neurons, induced pluripotent stem cells, cell transplantation, nonhuman primate model, Macaca fascicularis, MPTP-induced neurotoxicity, midbrain dopaminergic neurons, spontaneous movement, neurite outgrowth, corin, tumor formation, cell survival, cell tracking, immune response, cell therapy
- MeSH terms
- Adult, Aged, Aged, 80 and over, Animals, Cell Survival, Disease Models, Animal, Humans, Macaca fascicularis, Magnetic Resonance Imaging, Male, Mesencephalon, Movement, Parkinson Disease, Serine Endopeptidases, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Neurites, Neostriatum, Regenerative Medicine, Cell Proliferation, Positron-Emission Tomography, Induced Pluripotent Stem Cells, Dopaminergic Neurons
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.